Anzeige
❌
Mehr »
Dienstag, 10.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 1,42 USD bis Juni 2027, die 200 % Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: ZAL111 | ISIN: DE000ZAL1111 | Ticker-Symbol: ZAL
Xetra
10.11.26 | 14:19
27,960 Euro
+2,01 % +0,550
1-Jahres-Chart
ZALANDO SE Chart 1 Jahr
5-Tage-Chart
ZALANDO SE 5-Tage-Chart
RealtimeGeldBriefZeit
28,04028,10014:51
28,07028,08014:51
ACCESS Newswire
131 Leser
Artikel bewerten:
(0)

Aimwell Partners: Your Patients Are Asking AI About You. AimwellBio Lets Every Physician See the Answer, Free.

For decades, doctors have been told to search their own name. AimwellBio is asking every physician in the country to run the new test: ask AI what it says about you

MIAMI, FL / ACCESS Newswire / November 10, 2026 / Aimwell Partners Inc. (OTC PINK:AIMN), parent company of AimwellBio, today invited every physician and practice in the United States to run a free AI Visibility Scan and see what AI answer engines say about them when a patient asks.

For a growing number of patients, the search for a doctor no longer starts with a page of links. It starts with a single AI-generated answer that names a few providers and leaves the rest out. A physician who is missing from that answer is missing from the decision, and most do not know whether they are in it.

"Physicians spend years building a reputation. They should be able to see in one minute whether AI knows it," said John Morgan, Chief Executive Officer of Aimwell Partners. "The old test was to search your own name. The new test is to ask AI. We built the scan so any practice can run it for free, today."

How the Free Scan Works

The AI Visibility Scan takes about one minute, requires no email registration, and checks whether an AI answer engine mentions the practice in its responses. It is available now at aimwellbio.com/scan.

Practices that want to act on the result can take the next step:

  • Gap Report ($49): identifies the visibility issues and recommends three priority actions.
  • Action Plan ($149): written improvements plus a follow-up assessment after 30 days.
  • Website implementation (from $499): changes made on the practice's own website, subject to an agreed scope of work.

Beyond the Scan: Get Featured

AimwellBio's Provider Verification Registry is an editorial directory, not a pay-for-placement listing. It brings a provider's licensure, accreditation, ownership and services into a single verified profile that patients and referring clinicians can read. The first profile, Vital Care of Shelton in Connecticut, is live, and the Company is accepting applications from physicians, practices, clinics and healthcare businesses to be featured next, including doctors of chiropractic and allied professionals.

The public can also nominate a healthcare professional or organization they believe deserves to be featured. Nominations are subject to verification and editorial review. To apply or nominate, visit aimwellbio.com or email corporate@aimwellbio.com.

About Aimwell Partners Inc.

Aimwell Partners Inc. (OTC PINK:AIMN), through its subsidiary AimwellBio, is building a healthcare intelligence and verification network that helps patients, partners and investors evaluate healthcare information, companies and providers. For more information, visit aimwellbio.com. Company disclosures are available at OTCMarkets.com/AIMN.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the Company's services, the expansion of its provider registry, and the growth of the AimwellBio network. Words such as "will," "intends," "expects" and similar expressions identify forward-looking statements. These statements are based on management's current expectations and involve risks and uncertainties, including market acceptance of the Company's services, changes in how AI answer engines operate, and the Company's need for additional capital. Actual results may differ materially. The scan reflects a point-in-time check of one AI answer engine; results vary by engine, wording and date, and a practice's appearance or absence is not a measure of clinical quality. The Company undertakes no obligation to update any forward-looking statement except as required by law. Investors should review the Company's disclosures at OTCMarkets.com/AIMN.

Contact

John Morgan, Chief Executive Officer
Aimwell Partners Inc.
corporate@aimwellbio.com

SOURCE: Aimwell Partners



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/business-and-professional-services/your-patients-are-asking-ai-about-you.-aimwellbio-lets-every-phy-1249198

© 2026 ACCESS Newswire
Historische Öl-Krise - 5 Aktien, die davon profitieren!
Der Iran-Krieg hat den globalen Energiemarkt erschüttert. Zerstörte Förderanlagen, ausgefallene Transportwege und fehlende Raffineriekapazitäten sorgen dafür, dass nicht nur Rohöl, sondern vor allem Benzin und Diesel knapp und teuer bleiben könnten. Selbst ein Ende der Kämpfe würde das Problem nicht über Nacht lösen, der Wiederaufbau der Energieinfrastruktur dürfte Jahre dauern.

Während viele Anleger jetzt auf ExxonMobil, Chevron oder Shell setzen, könnte das größere Potenzial längst woanders liegen. Denn hohe Ölpreise machen neue Investitionen in Förderung, Transport und Verarbeitung wieder attraktiv. Davon profitieren vor allem jene Unternehmen, die Bohrtechnik, Ausrüstung und Dienstleistungen bereitstellen oder bereits über wertvolle Infrastruktur verfügen.

Hier dürfte die zweite Welle des Öl-Booms entstehen. Statt den bereits stark gelaufenen Produzenten hinterherzulaufen, können Anleger auf die Unternehmen setzen, die am milliardenschweren Wiederaufbau der globalen Energieinfrastruktur verdienen.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, die von der historischen Öl-Krise besonders profitieren könnten.

Jetzt den kostenlosen Report sichern und die möglichen Gewinner der zweiten Öl-Welle entdecken!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.